Molecular Partners Ag shares rise 1.76% intraday after EQT Life Sciences invests $44 million in Cyted Health.

Molecular Partners Ag rose 1.76% intraday, with the company's stock price increase potentially influenced by the recent funding round of Cyted Health, a leading gastrointestinal (GI) molecular diagnostics company. EQT Life Sciences led a USD 44 million Series B financing round, with co-leads Advent Life Sciences and British Business Bank, and continued support from existing investors Morningside and BGF. The financing includes a non-dilutive contribution from a strategic partnership with HCA Healthcare. The funds will be used to accelerate the commercial expansion of Cyted's diagnostics platform in the US, consolidate existing commercial success across the UK, and expand its portfolio of advanced diagnostic.